Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent Cancers

Trial Profile

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top